Indivior Plc - Company Profile
Powered by
All the data and insights you need on Indivior Plc in one report.
- Save hours of research time and resources with
our up-to-date Indivior Plc Strategy Report
- Understand Indivior Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Indivior Plc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The focus on R&D activities, lead product Sublocade, and strong distribution channels are its strengths, even as huge dependence on a few customers and history of operating loss are major causes for concern to the company. Indivior could benefit from strategic agreements, strategic acquisitions and regulatory approvals. However, dependence on third party payors, government regulations, and huge competition could affect the company's growth.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer